Table 10Koliopoulos et al36: Expected Tests (Screening and Triage), Incremental Tests, Life-Years, Incremental Life-Years, and Incremental Tests per Life-Year (ITLY) for Strategies Identified as Efficient*

StrategyTestsIncremental TestsLife-YearsIncremental Life-YearsITLY
No intervention069016.30
Cytology, q5, age 21116581165869205.11188.8162
Cytology, q3, age 2118997733969229.3724.26303
Cytology, q2, age 2127929893269241.1211.75760
Cytology, q1, age 21504162248769251.109.982253
*

Per 1,000 women. Age at which to begin screening is fixed at 21 years. For the combined cytology and HPV testing strategies, cytology-based screening is assumed before age 30 years, with a repeat cytology test for ASC-US results. The strategy of cytology and HPV testing is assumed to begin at age 30 years.

From: Addendum

Cover of Screening for Cervical Cancer: A Decision Analysis for the U.S. Preventive Services Task Force
Screening for Cervical Cancer: A Decision Analysis for the U.S. Preventive Services Task Force [Internet].
Evidence Syntheses, No. 86s.
Kulasingam SL, Havrilesky L, Ghebre R, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.